Clinical trial / 2017
Oral nicotinamide riboside was well tolerated and doubled steady-state whole blood NAD+ levels in healthy volunteers.
In an open-label pharmacokinetic study, 8 healthy volunteers took 250 mg oral nicotinamide riboside (NR) on Days 1 and 2, which was uptitrated to 1000 mg twice daily on Days 7 and 8, followed by a 24-hour pharmacokinetic evaluation on Day 9. Oral NR was well tolerated with no adverse events. Significant increases from baseline to steady-state mean concentrations were observed for both NR (p = 0.03) and NAD+ (p = 0.001), with NAD+ increasing by 100%. Absolute changes from baseline to Day 9 in NR and NAD+ levels were highly correlated (R2 = 0.72, p = 0.008).
- Study type
- Open-label, non-randomized pharmacokinetic study
- Who was studied
- 8 healthy volunteers
- What was measured
- Human pharmacokinetics of oral NR and whole blood NAD+ levels
THE PAPER
An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers.
Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD. PLoS One, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.